Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Future directions in CVD prevention

10 Oct 2018

A comprehensive approach involving a combination of LDL-cholesterol (LDL-C) lowering and anti-inflammatory therapy may improve clinical outcomes for appropriately selected patients at risk of cardiovascular disease (CVD), according to Dr San-Hyun Kim of the Seoul National University in Korea.

“LDL-C is the primary target of treatment, and studies have shown that the lower the level, the greater the risk reduction,” said Kim. [N Engl J Med 2004;3501495-1504; N Engl J Med 2005;352:1425-1435] “While statins are the drugs of choice for dyslipidaemia management, non-statin therapies are safe and effective when added to statin therapy.”

Adding ezetimibe has achieved incremental LDL-C lowering with better clinical prognosis. [N Engl J Med 2015;372:2387-2397] More recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have demonstrated significant 60 percent reductions in LDL-C with about 15 percent reductions in major adverse cardiovascular events (MACE) in patients already on statin therapy. [N Engl J Med 2017;376:1713-1722; Steg PG, et al, ACC 2018]

“Targeting the inflammatory interleukin pathway offers additional atheroprotection, independent of lipid lowering,” he argued. “For example, canakinumab, which targets interleukin-1b, has shown a 15 percent reduction in MACE. This has been attributed to significant 35–40 percent reductions in high sensitivity C-reactive protein [hsCRP] and interleukin-6, without any change in LDL-C.” [N Engl J Med 2017;377:1119-1131]

Kim emphasized that appropriate therapy selection based on patients’ underlying risk factors is crucial for successful atheroprotection and CVD risk reduction.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.